NXgenPort announces that it has entered into a license agreement with Mayo Clinic to improve product development and testing efforts.
FREMONT, CA: NXgenPort, a biomedical organization manufacturing products for remote patient monitoring, has announced that it has entered into a license agreement with Mayo Clinic to improve product development and testing efforts.
With the help of an implantable chemo-port catheter, NXgenPort's medical device assists providers such as the Mayo Clinic in monitoring cancer patients at home (patent pending). NXgenPort merges proven chemo-port efficiency with sensor technology to evaluate and remotely monitor early signs of complications by reporting and tracking patient response throughout treatment. According to the Chief Science Officer at NXgenPort, Dr. Rosanne Welcher, "NXgenPort will bring the benefits of remote patient monitoring to cancer patients, who may have limited support between their treatments. Advances in sensor technology are enabling better patient management in diabetes and heart function care – it is time for cancer patients to benefit as well."
Tufia Haddad, MD, a breast oncologist who also serves as a Medical Director in Mayo Clinic's Center for Digital Health, will be an advisor to NXgenPort under the terms of the agreement.
"Support from Dr. Haddad and Mayo Clinic will be invaluable in this critical stage of prototype development. So often, companies can waste money and time building products that do not fit within the workflow of clinicians or within the needs of organizations. Having early input from Dr. Haddad will help us build a product from the beginning that has value, scalability, and increased potential for adoption," said Cathy Skinner, NxgenPort Co-founder.
NXgenPort has developed a next-generation implantable chemo port-catheter that uses microelectronic sensors to allow remote patient management by monitoring and reporting physiological body systems during cancer treatment. NXgenPort is a start-up organization seeking funding to support product development and its intellectual property portfolio growth.